Latest Intelligence on Pharmaceuticals and Healthcare in Switzerland

Published within

« | ... | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Novartis: Eastern European generics to bring multiple rewards

Buying Slovenia's Lek gives an East European footing to Novartis' already large generics business. Lower R&D costs there should allow Novartis to move into the higher value specialty generics segment. The acquisition also gives Novartis revenues from generic Augmentin, which, unlike its own version of the product, are not dogged by risk of litigation.

Published By Datamonitor
04 Sep 2002
CommentWire
CommentWire

Novartis: dropping the healthy eating kick

Novartis wants to focus on its core higher-margin pharmaceutical business. But while the units may be Novartis's cast-offs, they are still top performers in the high-growth functional food market. This leaves them sure to attract a number of potential buyers, with Nestle and Danone the frontrunners.

Published By Datamonitor
05 Feb 2002
CommentWire
CommentWire

Novartis: continuing its infectious diseases drive

Novartis has bolstered its infectious disease pipeline with two acquisitions in as many days. The Swiss firm has signed a global agreement with US-based Human Genome Sciences for hepatitis C drug candidate Albuferon and made an offer for UK-based anti-infectives developer NeuTec Pharma.

Published By Datamonitor
07 Jun 2006
CommentWire
CommentWire

Novartis: building its antiviral arsenal

Novartis has announced a $507 million licensing deal with Human Genome Sciences for Albuferon, giving Novartis rights to co-promote the hepatitis C drug candidate in the US, with exclusive marketing and promotion rights outside the US. This is the Swiss firm's latest step in its strategy to build a versatile hepatitis C portfolio and become a leading player in this high-growth market.

Published By Datamonitor
06 Jun 2006
CommentWire
CommentWire

Novartis: bisphosphonate study should boost Zometa sales

A meta-analysis of bisphosphonate studies found that the drugs can lower skeletal morbidity in patients with metastatic disease. With Novartis' [NVS] Zometa recently gaining a sNDA for patients with bone metastases from advanced malignancies and this class of adjunct therapy becoming increasingly used, Zometa should be blockbuster by the end of 2003.

Published By Datamonitor
01 Sep 2003
CommentWire
CommentWire

Novartis: a small setback for Gleevec

Published By Datamonitor
25 Jun 2001
CommentWire
CommentWire

Novartis/Roche: a merger unlikely

Published By Datamonitor
09 May 2001
CommentWire
CommentWire

Novartis/Chiron: a promising cash injection

Novartis has finally satisfied Chiron's board after raising its takeover bid for the firm. This is good, if unsurprising, news for Novartis, as Chiron offers the Swiss drug maker growth opportunities in vaccines and biopharmaceuticals. Indeed, despite its recent woes, Chiron should be a good buy, enabling Novartis to become a key player in the increasingly important vaccine market.

Published By Datamonitor
02 Nov 2005
CommentWire
CommentWire

Novartis/BMS: it could be the end for Zelmac

Published By Datamonitor
20 Jun 2001
CommentWire
CommentWire

Novartis/Alnylam: racing against time in flu

Novartis and Alnylam have joined to advance pandemic flu therapeutics based on RNAi through initial clinical testing and eventually regulatory approval. This focus on RNAi R&D is driven by fears that current flu vaccines and antivirals might not be sufficient to protect against the H5N1 pandemic strain and only time will tell whether an approval is granted before the impending pandemic strikes.

Published By Datamonitor
21 Feb 2006

« | ... | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | » »|

No help is available.